Rhythm Biosciences is an Australian company focused on developing a low-cost, simple blood test for the detection of colorectal cancer.
The company recently withdrew their application to the Australian Therapeutic Goods Administration (TGA) for an Australian Register of Therapeutic Goods (ARTG) listing, due to logistical and supply chain timing constraints.
They are now preparing to submit a new application, and their test-kit, ColoSTAT®, has the potential to play a key role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer by increasing current screening rates.
The global addressable population for this test is over 800 million people, with almost 70% not currently screened due to the limitations of the current faecal based testing regime.